TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Use of natural products
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Drug-related problems identified
Endpoint domain: Adverse events/effects
Primary endpoint: in-stent restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent neointimal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stabilizing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom and living quality improving rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: annualized bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SPID scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global impression of change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Abnormal venous signals on three-dimensional TOF MRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of patients with no emesis and no nausea
Endpoint domain: Adverse events/effects
Primary endpoint: BDNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RSFC changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hospitalization for hyperkalemia
Endpoint domain: Adverse events/effects
Primary endpoint: discontinuation of study medication due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: CVD death
Endpoint domain: Mortality/survival
Primary endpoint: Fracture incidence
Endpoint domain: Mortality/survival
Primary endpoint: Microbiologic eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lag time before initiation of LDL oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propagation rate of LDL oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propagation rate of HDL oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unfavorable 12-month outcome
Endpoint domain: Mortality/survival
Primary endpoint: Implant stability as assessed by ISQ values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum iron levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: high sensitivity C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in tinnitus intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total pain score during transrectal prostate biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of modern radiation techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of refracture
Endpoint domain: Adverse events/effects
Primary endpoint: BBPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in weekly number of moderate to severe hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in allergic inflammation of bronchi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: alleviating symptoms of rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: increasing serum IFN-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Loss of total weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lean mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device or lead failure
Endpoint domain: Adverse events/effects
Primary endpoint: serum ferritin level at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in GAF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent episode of thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of cardiac death, acute myocardial infarction or development of heart failure
Endpoint domain: Mortality/survival
Primary endpoint: End-diastolic volume index (EDVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End-systolic volume index (ESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Half-life (t ½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline PCr levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total work production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean daily BG after 1st day of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of treatment failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in feelings of guilt related to placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: positive perceptions of interactions with staff
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in mean coefficient of fat absorption (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of perforation of glove barriers
Endpoint domain: Adverse events/effects
Primary endpoint: Depressive symptoms (SIGH SAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in objective symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in subjective symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking onset reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: foot pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: level of employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: hours worked per week
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: jobs acquired
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sensitivity to adenosine-provoked chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of modern contraceptive use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge and skills in assessing and managing clinical deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPPI (Modified Plaque Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative bleeding within first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood product requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean sensitivity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of ≥20% in intraocular pressure without using hypotensive medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: BCVA loss of ≥2 lines compared with best BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Worsening of visual field mean defect (VFMD) ≥2.5 dB compared with month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean anteroposterior side‐to‐side instrumented laxity difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Tegner score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Lysholm score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radiographical osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in vertebral fracture risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum safe dosages of tumescent lidocaine
Endpoint domain: Adverse events/effects
Primary endpoint: Serum lidocaine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of lidocaine toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in laparoscopic skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative edema and pain
Endpoint domain: Adverse events/effects
Primary endpoint: Analgesic consumption
Endpoint domain: Resource use
Primary endpoint: Osstell values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or higher treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Simulator Sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic prescription rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anticholinergic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance on the Trail Making Test Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NPI measures (including delusions, anxiety, and aberrant motor behavior)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean optical densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Readmission rate within 90 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ED50 of intrathecal hyperbaric ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean aortic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Receipt of guideline-concordant care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombin formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: In vitro bleeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: D-dimers release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic accuracy of FNA, MIBI, and FS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of diagnostic tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and numbness VAS scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mTCNS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Impact of FIT on diabetic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception during intrauterine procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: virologic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year incidence of major depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 12-month success rate
Endpoint domain: Mortality/survival
Primary endpoint: ETT intracuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and intensity of sore throat, hoarseness, and dysphagia
Endpoint domain: Adverse events/effects
Primary endpoint: Work ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Work-related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: PSA nadir greater than 0.5 ng/mL
Endpoint domain: Mortality/survival
Primary endpoint: PSA doubling time less than 9 months
Endpoint domain: Mortality/survival
Primary endpoint: Interval to PSA failure less than 30 months
Endpoint domain: Mortality/survival
Primary endpoint: plasma concentrations of arachidonic acid and DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma concentrations of EPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Continuation rates at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with contraceptive regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median number of bleeding days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of intraoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cessation of significant pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in post-operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of tonsillar fossae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFU mutans streptococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CFU lactobacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: D-dimer release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area decrease of thromboemboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linkage to care within 30 days of release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in care over 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival free of neurosensory disability
Endpoint domain: Mortality/survival
Primary endpoint: Liver function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of serious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of measles-like rash and fever
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titers to measles, mumps, and rubella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titer increase for varicella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone Mineral Density (BMD) at lumbar vertebrae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of anginal attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac power index at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lower levels of positive psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rating (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Not severely unwell (CGI-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scaled mental developmental scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scaled psychomotor developmental scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adjusted POMS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disease control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rates of clinical syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total response rates of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: P-adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: U-leptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: tissue uniformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epithelial surface appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphology improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma ascorbic acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: red cell reduced glutathione (GSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: scar hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: total scar score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in response efficacy for physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in response efficacy for diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported wholegrain consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of disability
Endpoint domain: Mortality/survival
Primary endpoint: workload at lactate threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate at lactate threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until return to normal activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma level of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma level of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery time of borborgmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma concentrations of selenium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of vitamin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of vitamin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sexual attraction perceptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral cues interpretation under alcohol influence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to detection of exacerbation requiring antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean 25[OH]D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal plasma flow response to captopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total score of PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microalbuminuria episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of contamination with room air (% air cont)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall cannulation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of alignment and length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: range of motion of the wrist and forearm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: global health status/quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression-Free Survival (PFS) rates
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with HBV DNA <15 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg lean mass increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Glycemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: loss in accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slowing of response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes